SE9702716D0 - Substituted phenylazacycloalkanes in the treatment of cognitive disorders - Google Patents

Substituted phenylazacycloalkanes in the treatment of cognitive disorders

Info

Publication number
SE9702716D0
SE9702716D0 SE9702716A SE9702716A SE9702716D0 SE 9702716 D0 SE9702716 D0 SE 9702716D0 SE 9702716 A SE9702716 A SE 9702716A SE 9702716 A SE9702716 A SE 9702716A SE 9702716 D0 SE9702716 D0 SE 9702716D0
Authority
SE
Sweden
Prior art keywords
treatment
cognitive disorders
substituted phenylazacycloalkanes
phenylazacycloalkanes
substituted
Prior art date
Application number
SE9702716A
Other languages
Swedish (sv)
Inventor
Ross Nicholas Waters
Clas Aake Sonesson
Nils Peter Stjernlof
Bengt Ronny Andersson
Soeren Lagerkvist
Lars Olov Hansson
Per Arvid Emil Carlsson
Original Assignee
Ross Nicholas Waters
Clas Aake Sonesson
Nils Peter Stjernlof
Anderson Bengt Ronny
Soeren Lagerkvist
Lars Olov Hansson
Carlson Per Arvid Emil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ross Nicholas Waters, Clas Aake Sonesson, Nils Peter Stjernlof, Anderson Bengt Ronny, Soeren Lagerkvist, Lars Olov Hansson, Carlson Per Arvid Emil filed Critical Ross Nicholas Waters
Priority to SE9702716A priority Critical patent/SE9702716D0/en
Publication of SE9702716D0 publication Critical patent/SE9702716D0/en
Priority to JP2000502769A priority patent/JP2001510156A/en
Priority to EP98934100A priority patent/EP1003513A1/en
Priority to AU83699/98A priority patent/AU8369998A/en
Priority to PCT/SE1998/001386 priority patent/WO1999003470A1/en

Links

Abstract

The invention relates to use of compounds according to formula (I) wherein n preferably is 2; R1 preferably is SO2CH3, R2 preferably is H, and R3 preferably is a C1-C8 alkyl, or pharmaceutically acceptable salts thereof for the production of a medicinal product for treatment and/or prevention of cognitive disorders. The invention also relates to methods for treatment and prevention of cognitive disorders, said method comprising administration of a compound according to formula (I).
SE9702716A 1997-07-15 1997-07-15 Substituted phenylazacycloalkanes in the treatment of cognitive disorders SE9702716D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9702716A SE9702716D0 (en) 1997-07-15 1997-07-15 Substituted phenylazacycloalkanes in the treatment of cognitive disorders
JP2000502769A JP2001510156A (en) 1997-07-15 1998-07-15 Pharmaceutical products and methods for treatment and prevention of cognitive disorders
EP98934100A EP1003513A1 (en) 1997-07-15 1998-07-15 Medicinal product and method for treatment and prevention of cognitive disorders
AU83699/98A AU8369998A (en) 1997-07-15 1998-07-15 Medicinal product and method for treatment and prevention of cognitive disorders
PCT/SE1998/001386 WO1999003470A1 (en) 1997-07-15 1998-07-15 Medicinal product and method for treatment and prevention of cognitive disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702716A SE9702716D0 (en) 1997-07-15 1997-07-15 Substituted phenylazacycloalkanes in the treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
SE9702716D0 true SE9702716D0 (en) 1997-07-15

Family

ID=20407750

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702716A SE9702716D0 (en) 1997-07-15 1997-07-15 Substituted phenylazacycloalkanes in the treatment of cognitive disorders

Country Status (5)

Country Link
EP (1) EP1003513A1 (en)
JP (1) JP2001510156A (en)
AU (1) AU8369998A (en)
SE (1) SE9702716D0 (en)
WO (1) WO1999003470A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2002056745A2 (en) * 2000-10-12 2002-07-25 Pharmacia & Upjohn Company Method of treating parkinson's disease
US6670378B2 (en) 2001-05-08 2003-12-30 Pharmacia & Upjohn Company Method of treating Parkinson's disease
DK2618826T3 (en) 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
HUE060353T2 (en) * 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Use of pridopidine to improve memory
AR105434A1 (en) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh PROCESS TO PREPARE PRIDOPIDINE
CA3151507A1 (en) 2016-08-24 2018-03-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545755A (en) * 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
US5633377A (en) * 1990-12-28 1997-05-27 Neurogen Corporation 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
KR100196888B1 (en) * 1991-04-17 1999-06-15 파마시아 앤드 업죤 컴패니 New centrally acting substituted phenylazacycloalkanes
DE4140540A1 (en) * 1991-12-09 1993-06-17 Bayer Ag NEW AZAHETEROCYCLYLMETHYL-CHROMANE

Also Published As

Publication number Publication date
AU8369998A (en) 1999-02-10
JP2001510156A (en) 2001-07-31
EP1003513A1 (en) 2000-05-31
WO1999003470A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
MY117896A (en) Quinazoline derivatives
NO306464B1 (en) Benzimidazole compounds, pharmaceutical compositions comprising such compounds, and the use of the compounds for the manufacture of medicaments
AP2002002637A0 (en) Novel piperazine
NZ514487A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
HUP9802762A2 (en) Diphenylmethylene piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
SE9702716D0 (en) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
DE69030665T2 (en) (1,2N) AND (3,2N) -BOXYCLICAL-2-AMINO-TETRALINE DERIVATIVES
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
AU3386299A (en) N-aryloxyethylamine derivatives for the treatment of depression
SE9802546D0 (en) Medicinal product and method for treatment and prevention of dyskinesia
DK0804186T3 (en) Indolditerpenalkaloid compounds
NO985063D0 (en) Pyridyl and pyrimidyl piperazines in the treatment of substance abuse disorders
ATE250027T1 (en) AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISEASES
NO20003138L (en) New application of local anesthetics to vascular headaches
PT1082116E (en) USE OF 4-PIPERIDINOMETHANOL DERIVATIVES IN THE TREATMENT OF DISORDERS OF NEURODESVOLVEMENT
CA2050875A1 (en) 3-(1h-indazol-3-yl)-4-pyridinamines, a process and intermediates for their preparation and their use as medicaments
ZA939153B (en) Use of idazoxan and its derivatives for the preparation of a medicinal product intended for the treatment of parkinson's disease and its development
DE69619088D1 (en) Quinoxaline derivatives used to treat tinnitus
MXPA98005355A (en) 5-[(heteroaryl) alkyl]-3 -oxo-pyrido [1, 2-a] benzimidazole -4-carboxamide derivatives useful in treating central nervous system disorders.
DE69902142T2 (en) AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISEASES
EP0794184A4 (en) 6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same
DK0950053T3 (en) New benzoylalkyl, 1,2,3,6-tetrahydropyridine derivatives
FI933652A0 (en) FOER REQUIREMENTS FRAMSTAELLNING AV 1-OSUBSTITUERADE 3-AMINOPYRROLER